United States Army Medical Research and Development Command

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium

Retrieved on: 
Wednesday, September 14, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, U.S. Defense Department firefighters, Therapy, United States Army Medical Research and Development Command, Traumatic brain injury, Trial of the century, Safety, Department, MTEC, Policy, Department of Defence, Research, Army, Concussion, Stroke, Government, Patient, Merrell Dow Pharmaceuticals Inc. v. Thompson, Goal, TBI, Brain, Drug discovery, Neurodegeneration, Department of the Army Civilian Police, Pharmaceutical industry, Risk management, Astrocyte

Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held in Orlando, FL.

Key Points: 
  • Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held in Orlando, FL.
  • Our first single-dose Phase 1 clinical study is proceeding as planned, and we have now completed all dose levels in the healthy volunteer subjects.
  • TBI is a top health priority of the military; 22 percent of all combat casualties in recent years are brain injuries, remarked retired Colonel Dallas Hack, M.D., M.P.H., and advisor to Astrocyte.
  • Astrocyte Pharmaceuticals Inc. is a privately held, clinical stage, drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients.

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

Retrieved on: 
Thursday, August 11, 2022
Knowledge, FDA, Death, Biomarker, The Lancet, NYSE, United States Department of Defense, United States Army Medical Research and Development Command, Ubiquitin, Neuron, Brain, CT, Transformative research, Disability, Research, Life, Blood, Probability, Plasma, Ubiquitin carboxy-terminal hydrolase L1, U.S. Department of Defense Strategy for Operating in Cyberspace, Patient, Prognosis, Twitter, Glial fibrillary acidic protein, National Health and Nutrition Examination Survey, GFAP, Mark (given name), United States Army Medical Materiel Agency, EDTA, University, Aline Miller, Emergency medicine, Head, Protein, United States Army Medical Research Institute of Infectious Diseases, LinkedIn, Neurology, Traumatic brain injury, Medical device, Medical imaging, TBI

Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.

Key Points: 
  • Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.
  • The researchers found that high values of the biomarkers, GFAP and UCH-L1, correlate with death and severe injury.
  • Test results are available approximately 15 minutes after a plasma sample is inserted in the test i-STAT cartridge.
  • More information is available at www.globalpointofcare.abbott/en/product-details/apoc/istat-tbi-plasma.html
    The i-STAT Alinity is an easy-to-use, portable blood analyzer that delivers real-time, lab-quality diagnostic test results.

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

Retrieved on: 
Thursday, August 11, 2022
Knowledge, FDA, Death, Biomarker, The Lancet, NYSE, United States Department of Defense, United States Army Medical Research and Development Command, Ubiquitin, Neuron, Brain, CT, Transformative research, Disability, Research, Life, Blood, Probability, Plasma, Ubiquitin carboxy-terminal hydrolase L1, U.S. Department of Defense Strategy for Operating in Cyberspace, Patient, Prognosis, Twitter, Glial fibrillary acidic protein, National Health and Nutrition Examination Survey, GFAP, Mark (given name), United States Army Medical Materiel Agency, EDTA, University, Aline Miller, Emergency medicine, Head, Protein, United States Army Medical Research Institute of Infectious Diseases, LinkedIn, Neurology, Traumatic brain injury, Medical device, Medical imaging, TBI

Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.

Key Points: 
  • Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.
  • The researchers found that high values of the biomarkers, GFAP and UCH-L1, correlate with death and severe injury.
  • Test results are available approximately 15 minutes after a plasma sample is inserted in the test i-STAT cartridge.
  • More information is available at www.globalpointofcare.abbott/en/product-details/apoc/istat-tbi-plasma.html
    The i-STAT Alinity is an easy-to-use, portable blood analyzer that delivers real-time, lab-quality diagnostic test results.

AiCure and Defense Health Agency to Develop Targeted PTSD Treatment for Service Members and Veterans

Retrieved on: 
Tuesday, July 12, 2022
Defense, Veteran, United States Army Futures Command, Precision medicine, Anxiety, Speech disorder, APTS, Product manager, National Defense Strategy (United States), Compliance, Course Correction, Diagnosis, Medicine, Vaccine, Artificial intelligence, Multimedia, Psychiatry, Service, Combat support agency, Comorbidity, Survival, United States Army Medical Research and Development Command, Digital, Defense Health Agency, Patient, CEO, Digital health, NEW, Program, NIH, Depression, Time, National, APT, United States Army Medical Materiel Agency, Health, AI, FDA, Quality of life, Research, Unified combatant command, Military Health System, Post-traumatic stress disorder, DHA, Biomarker, Pharmaceutical industry, Medical device, PTSD, School of Advanced Warfighting

By optimizing personalized treatment matching, the PTSD-DT Program and AiCure aim to improve service members' quality of life and maintain troop readiness, while also informing the development of future therapies.

Key Points: 
  • By optimizing personalized treatment matching, the PTSD-DT Program and AiCure aim to improve service members' quality of life and maintain troop readiness, while also informing the development of future therapies.
  • Eighty percent have at least one additional comorbidity such as depression, anxiety or substance abuse disorder, complicating diagnosis and treatment further1.
  • Despite the societal, financial, and emotional strain that PTSD exerts upon patients, treatment options remain scarce, with only two FDA approved therapies.
  • DHA supports the National Defense Strategy and Service Military Departments by leading the Military Health System as an integrated, highly-reliable system of readiness, medical training, and health.

Novel brain injury treatment tested in 1st human subject; drug conceived at UT Health San Antonio

Retrieved on: 
Thursday, June 16, 2022
Doctor of Philosophy, Laboratory, Patent, Safety, Science, Stroke, United States Army Medical Research and Development Command, Concussion, Office of Inspector General, U.S. Department of Health and Human Services, Traumatic brain injury, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, University of Texas Health Science Center at San Antonio, Brain, Anatomy, Research, Human, Neurodegeneration, University, University of Texas System, Clinical trial, U.S. Department of Defense Strategy for Operating in Cyberspace, Alzheimer's disease, Orbital Technologies Commercial Space Station, Workforce, Partnership, UT Health San Antonio Cancer Center, Food, Life, Translation, TBI, Patient, Pharmacokinetics, SAN, Neurology, Mouse, Pharmaceutical industry, Medical device

SAN ANTONIO and GROTON, Conn., June 16, 2022 /PRNewswire-PRWeb/ -- An experimental brain injury medication conceived in laboratories at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was tested Tuesday, June 14, in the first human subject, a clinical trial participant in Hungary. If the drug, called AST-004, performs well in human studies, it will be an urgently needed and novel treatment for stroke and traumatic brain injury (TBI) victims, including those with concussions. Plans are to study it as a chronic therapy for neurodegenerative diseases such as Alzheimer's, as well.

Key Points: 
  • SAN ANTONIO and GROTON, Conn., June 16, 2022 /PRNewswire-PRWeb/ -- An experimental brain injury medication conceived in laboratories at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was tested Tuesday, June 14, in the first human subject, a clinical trial participant in Hungary.
  • James D. Lechleiter, PhD , professor of cell systems and anatomy at UT Health San Antonio, made the discoveries that enabled AST-004 development.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is a primary driver for San Antonio's $42.4 billion health care and biosciences sector, the city's largest economic generator.
  • UT Health San Antonio is the largest research university in South Texas with an annual research portfolio of approximately $350 million.

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Retrieved on: 
Wednesday, June 15, 2022
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Manna, Doctor of Philosophy, Biomedical Research, MTEC, Department, Therapy, Drug development, Astrocyte, Biomedical technology, Safety, United States Army Medical Research and Development Command, Traumatic brain injury, Government, Concussion, Brain, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Pharmacokinetics, Trial of the century, Human, Neurodegeneration, Department of the Army Civilian Police, Ageing, Drug discovery, Program, Policy, Health, Acquisition, Pharmacology, Patient, TBI, Military personnel, Army, Goal, Department of Defence, Pharmaceutical industry, Stroke

The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke and traumatic brain injury (TBI) victims, and as a chronic treatment for neurodegenerative diseases like Alzheimers.

Key Points: 
  • The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke and traumatic brain injury (TBI) victims, and as a chronic treatment for neurodegenerative diseases like Alzheimers.
  • The primary objective of the first-in-human study, designated AST-004-1-02, is to evaluate the safety, tolerability and pharmacokinetic profile of AST-004 in healthy normal human subjects.
  • Astrocyte Pharmaceuticals Inc. is a privately held, clinical stage, drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients.
  • The company is committed to proving the cerebroprotective benefits of enhancing astrocyte function, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, traumatic brain injury, concussion, and neurodegenerative disorders such as Alzheimers disease.

Trauma Triage Treatment and Training Decision Support (4TDS)

Retrieved on: 
Friday, June 10, 2022
Amos, Science, Navy, Army, Vital signs, Internal bleeding, Research, Transport, Doctor of Philosophy, United States Army Medical Research and Development Command, Joint Base San Antonio, Air force, Artificial intelligence, United States Army Medical Materiel Agency, Outline of health sciences, TCCC, Tactical Combat Casualty Care, Bleeding, Trauma, Probability, Nursing, Solution, Uniformed Services University of the Health Sciences, Biomedical engineering, Systems analysis, FDA, Triage, Training, Poi, Disease, Mortality, Risk, Biotechnology, USUHS, Shock, Diagnosis, MD, Oxygen saturation (medicine), Pacific Northwest National Laboratory, ARA, Engineering, PFC, Health, Mayo Clinic, Clinical professor, JBSA, Medical device

To meet that need, Applied Research Associates, Inc. (ARA), the Mayo Clinic, and Ambient Clinical Analytics developed the Trauma Triage Treatment and Training Decision Support (4TDS) system.

Key Points: 
  • To meet that need, Applied Research Associates, Inc. (ARA), the Mayo Clinic, and Ambient Clinical Analytics developed the Trauma Triage Treatment and Training Decision Support (4TDS) system.
  • Early engagement with experienced military medics and clinicians from all services ensured 4TDS reflects their mental models and work processes.
  • It also built support among potential users should the system transition to operational use.
  • Dr. Herasevich led shock prediction model development and testing with support from ARAs Adam Amos-Binks, PhD.

MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns

Retrieved on: 
Tuesday, May 31, 2022
Program, MBA, Risk, Good tissue practice, Engineering, U.S. Navy Diving Manual, MTEC, NMRC, Biomedical technology, Disease, Survival, Naval Medical Research Center, Â, Dehydration, Journal, Operation Enduring Freedom, United States Army Medical Research and Development Command, Science, Chief of Naval Operations Strategic Studies Group, Patient, Burn, Sterilization, University, United States Armed Forces, Health, University of Arizona, Mortality, Military personnel, Research, Industry, Tissue, Safety, FACS, Wound healing, Medical corps, Allotransplantation, MD, OTA, GLOBE, Pharmaceutical industry

MARIETTA, Ga., May 31, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced receiving a $4.6 Million award to evaluate PURION® processed Dehydrated Human Amnion Chorion Membrane (DHACM) as an advanced treatment option for wound and burn care. The award from the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command, is sponsored and will be managed by the Naval Medical Research Center (NMRC) to advance medical treatments for combat wounds and burns.

Key Points: 
  • This award will be used to advance the clinical understanding of DHACM, specifically in treating acute injuries and preventing initially partial-thickness burns from deteriorating to full-thickness burns, which can be life threatening.
  • To address combat and burn injuries, NMRC funded the award that will be directed toward research evaluating wound healing and burn conversion prevention capabilities of DHACM.
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • The consortium focuses on the development of medical solutions that protect, treat, and optimize the health and performance of U.S. military personnel.

Amicrobe Selects Clinical Formulation for Amicidin-α PFC, Supported by Department of Defense for Prolonged Field Care of Injured Warfighters

Retrieved on: 
Tuesday, May 10, 2022
Biomedical Research, Military personnel, CSO, PFC, Nature, Company, Paola Lattus, Army, Department of Defence, Fungus, Infection, Science, Virus, Trauma, Environment, MTEC, Health, Biomedical technology, United States Army Medical Research and Development Command, CEO, Technology, Bacteria, Science and technology, United States Department of Defense, Acquisition, Pharmaceutical industry

CARLSBAD, Calif., May 10, 2022 /PRNewswire/ -- Amicrobe, Inc. develops synthetic biologics with physical and antimicrobial properties, called Amicidins. Today, the Company announced the selection of lead clinical formulation for Amicidin-α PFC (Prolonged Field Care), a key milestone in the development of a new product for military field care of injured warfighters.

Key Points: 
  • Today, the Company announced the selection of lead clinical formulation for Amicidin- PFC (Prolonged Field Care), a key milestone in the development of a new product for military field care of injured warfighters.
  • Amicidin- PFC is a dry powder formulation of Amicidin- intended to prevent infection of traumatic wounds for prolonged periods (up to 72 hours).
  • Amicidin- PFC is supported by a $3.99M US Department of Defense award issued in August 2021 for development from formulation through a Phase 1/2a clinical trial.
  • "We are excited for its potential to help injured warfighters prevent limb- and life-threatening infections in the field."

Amicrobe Selects Clinical Formulation for Amicidin-α PFC, Supported by Department of Defense for Prolonged Field Care of Injured Warfighters

Retrieved on: 
Tuesday, May 10, 2022
Biomedical Research, Military personnel, CSO, PFC, Nature, Company, Paola Lattus, Army, Department of Defence, Fungus, Infection, Science, Virus, Trauma, Environment, MTEC, Health, Biomedical technology, United States Army Medical Research and Development Command, CEO, Technology, Bacteria, Science and technology, United States Department of Defense, Acquisition, Pharmaceutical industry

CARLSBAD, Calif., May 10, 2022 /PRNewswire/ -- Amicrobe, Inc. develops synthetic biologics with physical and antimicrobial properties, called Amicidins. Today, the Company announced the selection of lead clinical formulation for Amicidin-α PFC (Prolonged Field Care), a key milestone in the development of a new product for military field care of injured warfighters.

Key Points: 
  • Today, the Company announced the selection of lead clinical formulation for Amicidin- PFC (Prolonged Field Care), a key milestone in the development of a new product for military field care of injured warfighters.
  • Amicidin- PFC is a dry powder formulation of Amicidin- intended to prevent infection of traumatic wounds for prolonged periods (up to 72 hours).
  • Amicidin- PFC is supported by a $3.99M US Department of Defense award issued in August 2021 for development from formulation through a Phase 1/2a clinical trial.
  • "We are excited for its potential to help injured warfighters prevent limb- and life-threatening infections in the field."